Drug Approval | February 03, 2022
USFDA approves first generic of Restasis
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
This test analyses samples in VTM directly without the need for RNA extraction step
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
Effectiveness of Covaxin against the Omicron variant is currently being studied
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Subscribe To Our Newsletter & Stay Updated
